Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of anxa6 expression inhibitor in preparation of medicine for treating lung cancer

A technology for inhibitors and lung cancer, applied in drug combinations, gene therapy, anti-tumor drugs, etc., can solve the problems of ANXA6 function that have not been reported, and achieve the effect of growth rate inhibition

Active Publication Date: 2021-10-15
BEIJING CHEST HOSPITAL CAPITAL MEDICAL UNIV +1
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] At present, there is no relevant report on the function of ANXA6 in the occurrence, migration and invasion of lung cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of anxa6 expression inhibitor in preparation of medicine for treating lung cancer
  • Application of anxa6 expression inhibitor in preparation of medicine for treating lung cancer
  • Application of anxa6 expression inhibitor in preparation of medicine for treating lung cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0071] Embodiment 1, cell culture and lentivirus infection

[0072] Cell culture conditions are: 37 ° C, 5% CO 2 Static cultivation.

[0073] The basal medium used in the examples is: take serum-free RPMI-1640 medium, add fetal bovine serum to a concentration of 10% v / v, add penicillin to a concentration of 100 U / ml, and add streptomycin to a concentration of 0.1 mg / ml.

[0074] 1. Cell culture, subculture and inoculation

[0075] 1. 801D cells and H1299 cells were inoculated in basal medium.

[0076] 2. Subculture the 90% confluent cells, add trypsin digestion solution, and digest at 37°C for about 5 minutes until the cells are completely digested into single cells.

[0077] 3. Add the basal medium and pipette to mix. After mixing, count with a Muse cell counter.

[0078] 4. Inoculate 801D cells and H1299 cells in a 96-well plate, the number of cells per well is 4000, and each type of cells is inoculated in 12 wells.

[0079] 5. 37°C, 5% CO 2 Incubate overnight.

[0...

Embodiment 2

[0085] Example 2, detection of ANXA6 gene knockout effect

[0086] 1. Extraction of total cell protein

[0087] 1. Cells infected with virus and screened by Puromycin were cultured in basal medium until 70% to 80% confluence.

[0088] 2. Collect two groups of cells, perform trypsinization, centrifuge and discard the supernatant.

[0089] 3. Wash the cells 3 times with pre-cooled normal saline to remove the residual medium, and aspirate the supernatant as much as possible after the last centrifugation.

[0090] 4. Prepare cell lysate: 1ml lysate + 10μl protease inhibitor (Cocktail) + 1μl dithiothreitol (DTT) + 7μl PMSF, mix well and place on ice.

[0091] 5. For the cells collected in step 3, add 100 μl of cell lysate for every 1 million cells, lyse on ice for 10-30 minutes, and mix well every 5 minutes.

[0092] 6. Centrifuge in a low-temperature high-speed centrifuge, the centrifugation conditions are: 13000rpm, 4°C, 10min.

[0093] 7. Aliquot the supernatant and store at...

Embodiment 3

[0113] Example 3, detection of the effect of ANXA6 knockout on cell proliferation

[0114] 1. Monoclonal cell screening

[0115] 1. The 801D and H1299 cells with ANXA6 gene knockout were cultured in basal medium to 70% to 80% confluence.

[0116] 2. Add trypsin digestion solution and digest at 37°C for about 5 minutes until the cells are completely digested into single cells. Add basal medium, mix well, and discard the supernatant after centrifugation. Resuspend with basal medium, and count with Muse cell counter after resuspension.

[0117] 3. Dilute according to the counting results, and the final dilution is 10 cells / ml.

[0118] 4. After mixing, inoculate a 96-well plate with 100 μl of cell suspension per well.

[0119] 5. 37°C, 5% CO 2 Let stand and observe after one week.

[0120] 6. Subculture and amplify according to the growth of monoclonal cells.

[0121] 7. According to the detection method shown in Example 2, the ANXA6 knockout condition of the monoclonal ce...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an application of an ANXA6 expression inhibitor in the preparation of a drug for treating lung cancer. The research of the present invention finds that after the expression of ANXA6 is inhibited, the proliferation of lung cancer cells is significantly inhibited, the colony formation ability of lung cancer cells is inhibited, the subcutaneous tumorigenesis ability of lung cancer cells is significantly reduced, and the growth rate of tumors is significantly inhibited. The present invention also provides a drug for treating lung cancer. The drug utilizes the principle of CRISPR gene editing to knock out the ANXA6 gene in lung cancer cells, thereby playing a therapeutic effect on lung cancer.

Description

technical field [0001] The invention relates to the field of biotechnology, in particular to the application of an ANXA6 expression inhibitor in the preparation of medicines for treating lung cancer. Background technique [0002] The CRISPR / Cas system is a defense system for bacteria and archaea against foreign DNA invasion, which can excise the invading foreign nucleic acid sequence. The CRISPR / Cas9 system consists of two molecules, the Cas9 protein and the guide RNA (Guide RNA, gRNA or small-guide RNA, sgRNA). The Cas9 protein is a nuclease that depends on the sgRNA and can only be activated when it works with the sgRNA. The process of recognizing and cutting genomic DNA by itself. The sgRNA guides Cas9 to cut the target sequence through the reverse complementary sequence to the target genomic DNA, resulting in double-strand DNA breaks. Under the condition of no template, the insertion or deletion of DNA bases occurs, thereby causing frameshift mutations to achieve gene k...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K48/00A61K31/7088A61K38/46A61K39/395A61K45/00A61P11/00A61P35/00
CPCA61K31/7088A61K38/465A61K39/395A61K45/00A61K48/0025A61K48/005A61P11/00A61P35/00
Inventor 李伟英李嘉恒王子宇顾勐谭金晶张丽娜
Owner BEIJING CHEST HOSPITAL CAPITAL MEDICAL UNIV